EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieKohortenstudie

Comparative Outcomes of Babesiosis in Immunocompromised and Nonimmunocompromised Hosts: A Multicenter Cohort Study

Loukas Kakoullis iD, Carolyn D Alonso iD, Rebecca Burns, Muneerah M Aleissa, Esther Arbona Haddad, Andy J Kim, Rebecca Rooks iD, Bridget Yates, Urwah Kanwal, Nicholas P Morreale, Alexandra Morgan iD, Ramy Arnaout iD und 11 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf034 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Loukas Kakoullis und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mount Auburn Hospital, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Babesiosis, Immunocompromised Host. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Babesiosis poses significant risks of adverse outcomes in individuals with immunocompromising conditions (IC) and asplenia/hyposplenia (AH). This study compares clinical outcomes between these vulnerable groups and immunocompetent patients.

Methods

This multicenter retrospective cohort study included adult patients with laboratory-confirmed babesiosis from 2009 to 2023. Complications, management, and outcomes were compared between patients with IC/AH (ICAH) and without ICAH (immune intact cohort).

Results

Of 225 patients (mean age 66 years, 36% female), 112 were ICAH. ICAH patients had higher median peak parasitemia (2.8% vs 0.9%, P < .0001) and higher rates of complications, including acute kidney injury (24% vs 11%, P = .016) and acute respiratory distress syndrome (11% vs 4%, P = .041), and were more likely to undergo packed red blood cell transfusion (31% vs 17%, P = .023) and exchange transfusion (18% vs 6%, P = .008). Treatment duration was longer in the ICAH cohort (median 27 vs 10 days, P < .001), particularly in those with both IC and AH (median 43 days, P = .003). ICAH patients had higher 12-month all-cause mortality (7% vs 1%, P = .019) and recurrence rates (8% vs 0%, P = .001). Hematologic malignancy (odds ratio = 7.0, P = .023) and B-cell–depleting therapies (odds ratio = 9.4, P = .015) were significant predictors of recurrence. Despite most patients undergoing follow-up testing with blood smears and polymerase chain reaction, these did not reliably predict recurrence.

Conclusions

Patients with ICAH with babesiosis experience more severe disease and higher complication rates. Follow-up testing, including blood smear and polymerase chain reaction, did not reliably predict recurrence, highlighting the need for more effective monitoring strategies in these high-risk populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BabesiosisImmunocompromised HostHumansMaleFemaleAgedRetrospective StudiesMiddle AgedTreatment OutcomeAged, 80 and overAdultCohort Studies

Stichwörter der Autor:innen

Babesia microtiTNF inhibitorsrelapserituximabtransplant infectious diseases

Autor:innen und Institutionen

  • Department of Medicine, Mount Auburn Hospital, Cambridge, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • College of Pharmacy, Department of Pharmacy Practice, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

ORCID-Profile: Loukas Kakoullis, Carolyn D Alonso, Rebecca Rooks, Alexandra Morgan, Ramy Arnaout, Alexandra Tong, Natalie E Izaguirre, Jessica S Little, Sarah P Hammond, Amy C Sherman, Courtney E Harris

Zitieren

APA

Kakoullis, L., Alonso, C. D., Burns, R., Aleissa, M. M., Haddad, E. A., Kim, A. J., Rooks, R., Yates, B., Kanwal, U., Morreale, N. P., Morgan, A., Arnaout, R., Tong, A., Izaguirre, N. E., Little, J. S., Hammond, S. P., Montgomery, M. W., Sherman, A. C., Maguire, J. H., …, & Harris, C. E. (2025). Comparative Outcomes of Babesiosis in Immunocompromised and Nonimmunocompromised Hosts: A Multicenter Cohort Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf034

Vancouver

Kakoullis L, Alonso CD, Burns R, Aleissa MM, Haddad EA, Kim AJ, et al. Comparative Outcomes of Babesiosis in Immunocompromised and Nonimmunocompromised Hosts: A Multicenter Cohort Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf034

BibTeX
@article{Kakoullis2025,
  author = {Kakoullis, Loukas and Alonso, Carolyn D and Burns, Rebecca and Aleissa, Muneerah M and Haddad, Esther Arbona and Kim, Andy J and Rooks, Rebecca and Yates, Bridget and Kanwal, Urwah and Morreale, Nicholas P and Morgan, Alexandra and Arnaout, Ramy and Tong, Alexandra and Izaguirre, Natalie E and Little, Jessica S and Hammond, Sarah P and Montgomery, Mary W and Sherman, Amy C and Maguire, James H and Woolley, Ann E and Baden, Lindsey R and Issa, Nicolas C and Harris, Courtney E},
  title = {Comparative Outcomes of Babesiosis in Immunocompromised and Nonimmunocompromised Hosts: A Multicenter Cohort Study},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf034}
}
Kostenlos starten →